See more : Multi-Metal Development Ltd. (MLYCF) Income Statement Analysis – Financial Results
Complete financial analysis of Chromocell Therapeutics Corporation (CHRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chromocell Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Topkey Corporation (4536.TW) Income Statement Analysis – Financial Results
- Switch, Inc. (SWCH) Income Statement Analysis – Financial Results
- Global Acquisitions Corporation (AASP) Income Statement Analysis – Financial Results
- Canada Energy Partners Inc. (CNDPF) Income Statement Analysis – Financial Results
- Carver Bancorp, Inc. (CARV) Income Statement Analysis – Financial Results
Chromocell Therapeutics Corporation (CHRO)
About Chromocell Therapeutics Corporation
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 199.93K |
| Cost of Revenue | 2.58M | 391.73K | 209.05K | 138.59K |
| Gross Profit | -2.58M | -391.73K | -209.05K | 61.35K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 30.68% |
| Research & Development | 2.58M | 391.73K | 209.05K | 138.59K |
| General & Administrative | 4.28M | 1.93M | 629.95K | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.28M | 1.93M | 629.95K | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.86M | 2.32M | 839.00K | 1.55M |
| Cost & Expenses | 6.86M | 2.32M | 839.00K | 1.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 518.51K | 140.43K | 253.00 | 1.68K |
| Depreciation & Amortization | 0.00 | 690.45K | 839.00K | 1.35M |
| EBITDA | -6.86M | -1.63M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -677.16% |
| Operating Income | -6.86M | -2.32M | -839.00K | -1.35M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -677.16% |
| Total Other Income/Expenses | -518.51K | -140.43K | 243.61K | 693.28K |
| Income Before Tax | -7.38M | -2.46M | -595.39K | -660.58K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -330.40% |
| Income Tax Expense | 0.00 | -690.45K | -839.00K | -1.35M |
| Net Income | -7.38M | -2.46M | -595.39K | -660.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -330.40% |
| EPS | -1.28 | -0.43 | -0.10 | -0.11 |
| EPS Diluted | -1.28 | -0.43 | -0.10 | -0.11 |
| Weighted Avg Shares Out | 5.77M | 5.77M | 5.77M | 5.77M |
| Weighted Avg Shares Out (Dil) | 5.77M | 5.77M | 5.77M | 5.77M |
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation...
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve...
Chromocell Announces Amendment to Stock Repurchase Plan
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has...
Chromocell to Participate in Life Sciences Investor Forum September 19th
FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences...
Chromocell Announces Stock Repurchase Plan
FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has...
Chromocell to Participate in the Virtual Investor Lunch Break Series
Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00...
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced that Randy Peck, a 20-year Paycom veteran, has been appointed to serve as Paycom's Chief Operating Officer, while...
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
Briones and Carey to join company's executive committee on Jan. 1, 2025 SAN FRANCISCO , May 22, 2024 /PRNewswire/ -- Prologis (NYSE: PLD) today announced Ed Nekritz and Colleen McKeown will retire as chief legal officer and chief human resources...
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance...
Chromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the...
Source: https://incomestatements.info
Category: Stock Reports